Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911777 | 0.87 | KIF11 (0.46) | HRH4TRPA1SCN5ASCN9AALDH1A1 | |
| SCHEMBL2312436 | 0.86 | HRH4 (0.43) | HRH4BACE2TRPA1SCN5ASCN9A | |
| SCHEMBL7076047 | 0.83 | HRH4 (0.38) | HRH4BACE2TRPA1SCN5ASCN9A | |
| SCHEMBL28194011 | 0.80 | HRH4 (0.41) | HRH4BACE2TRPA1SCN5ASCN9A | |
| SCHEMBL1038946 | 0.79 | HRH4 (0.41) | HRH4BACE2TRPA1SCN5ASCN9A | |
| SCHEMBL352769 | 0.79 | SLC22A12 (0.41) | HRH4TRPA1SCN5ASCN9APNMT | |
| SCHEMBL3644863 | 0.79 | APP (0.44) | HRH4TRPA1SCN5ASCN9APNMT | |
| SCHEMBL1039255 | 0.79 | AR (0.46) | HRH4BACE2TRPA1SCN5ASCN9A | |
| SCHEMBL16150577 | 0.78 | BACE2 (0.42) | HRH4BACE2TRPA1SCN5ASCN9A | |
| SCHEMBL7076049 | 0.78 | ALDH1A1 (0.56) | HRH4SCN9AALDH1A1KDM4EKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | claimed |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-03-25 | — | — | US | claimed |
| US-7645791-B2 | Salicylic anilides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-01-12 | — | — | US | claimed |
| US-20090005434-A1 | Novel Salicylic Anilides | NOVO NORDISK A/S (DK) | 2009-01-01 | — | — | US | claimed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | claimed |
| EP-1966182-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| EP-1888513-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | claimed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-20070004794-A1 | Novel salicylic anilides | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | claimed |
| WO-2006125778-A1 | NOVEL TRIFLUOROMETHOXY-SUBSTITUTED ARYL ANILIDES | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | claimed |
| EP-1689700-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051894-A1 | NOVEL SALICYLIC ANILIDES | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | claimed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2004062665-A1 | HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | HRH4 208/4885BACE2 4287/4885TRPA1 212/4885 |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | HRH4 317/4885BACE2 3782/4885TRPA1 343/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | HRH4 187/4885BACE2 4730/4885TRPA1 1806/4885 |
| US-20090005434-A1 | Novel Salicylic Anilides | FABP4, ADIPOR1, ADIPOR2 | HRH4 3143/4885BACE2 4668/4885TRPA1 2535/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | HRH4 471/4885BACE2 3579/4885TRPA1 294/4885 |
| US-20070004794-A1 | Novel salicylic anilides | FABP4, ADIPOR1, ADIPOR2 | HRH4 3143/4885BACE2 4668/4885TRPA1 2535/4885 |
| US-20100075932-A1 | NOVEL SALICYLIC ANILIDES | FABP4, ADIPOR1, ADIPOR2 | HRH4 3143/4885BACE2 4668/4885TRPA1 2535/4885 |
| US-20080255240-A1 | Sulfonamide Derivatives | FABP4, SQOR, CS | HRH4 2972/4885BACE2 4050/4885TRPA1 626/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | HRH4 187/4885BACE2 4730/4885TRPA1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.